Search the Newsreel

Arcadia Biosciences earnings missed by $1.53, revenue fell short of estimates

Dare Bioscience earnings beat by $0.11, revenue topped estimates

Dare Bioscience (NASDAQ: DARE) reported Q2 EPS of $-0.2000, surpassing analyst estimates by $0.11, and revenue of $187.55K, significantly beating the consensus estimate of $1.67K. Despite the positive earnings surprise, the company's stock has seen a decline of -36.87% over the last three months …

Jade Biosciences (JBIO) Shares Just Moved, So What Is Going On?

Jade Biosciences (JBIO) recently released its Q2 2026 results, reporting a net loss of $55.77 million. Despite strong year-to-date share price returns of 63.91% and a 1-year total shareholder return of 216.64%, the stock's 90-day return declined, and it trades well below the average …

H.C. Wainwright Maintains Jade Biosciences(JBIO.US) With Buy Rating, Maintains Target Price $55

H.C. Wainwright has reiterated its Buy rating for Jade Biosciences (JBIO.US), keeping the target price at $55. This indicates continued confidence in the company's performance and future prospects from the analyst firm.

Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard?

On July 22, Arcus Biosciences, Inc. (NYSE:RCUS) and Summit Therapeutics Inc. (NASDAQ:SMMT) announced a major clinical trial collaboration to combine Arcus's casdatifan (an investigational HIF-2α inhibitor) with Summit's ivonescimab (an investigational PD-1/VEGF bispecific antibody). The study aims to evaluate the safety and efficacy of …

Arcus Biosciences (RCUS) Reported Q2 2026 Results, Is The Stock A Bargain?

Arcus Biosciences reported Q2 2026 results with $41 million in revenue and a $91 million net loss, along with new full-year revenue guidance. The stock has seen significant price returns (16.07% in 90 days, 24.35% YTD), and a current valuation suggests it is 24% …

Caribou Biosciences (NASDAQ:CRBU) Releases Earnings Results, Beats Expectations By $0.08 EPS

Caribou Biosciences (NASDAQ:CRBU) reported a quarterly loss of $0.24 per share, surpassing analyst expectations by $0.08, though revenue of $1.50 million fell short of estimates. Following the announcement, shares declined by 5.3% to $1.61. Despite substantial losses and a negative net margin, institutional investors …

Pulse Biosciences (PLSE) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Investor Relations - Philip TaylorCo-Chair of the Board and Chief Executive Officer - Paul LaVioletteChief Financial Officer - Jon SkinnerCo-Chair of the Board - Bob Duggan Need a …

NovaBridge Biosciences to report H1FY26 results on Aug 20

NovaBridge Biosciences (NASDAQ: NBP) will hold a webcast on August 20, 2026, to discuss its financial results for the first half ended June 30, 2026, and provide a corporate update. The company, focused on oncology and ophthalmology programs, will host the webcast at 9:00 …

Inhibrx Biosciences (NASDAQ:INBX) Posts Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Inhibrx Biosciences (NASDAQ:INBX) reported a quarterly loss of $2.34 per share, missing analysts' consensus estimates by $0.06. Following the announcement, the stock fell 1.4% to $97.01. Despite mixed analyst sentiment resulting in a "Hold" rating, institutional investors hold a significant 82.46% of the company's …

Earnings call transcript: Daré Bioscience Q2 2026 loss narrows as stock jumps after hours

Daré Bioscience reported a narrowed Q2 2026 net loss of $3.0 million, down from $4.0 million year-over-year, with revenue reaching $0.2 million. The company's stock initially fell but then surged 21.2% after hours, as investors reacted positively to progress in commercialization with new product …

Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Corbus Pharmaceuticals (CRBP)

This article highlights bullish sentiments from analysts for two healthcare stocks: Aura Biosciences Inc (AURA) and Corbus Pharmaceuticals (CRBP). LifeSci Capital and H.C. Wainwright maintained Buy ratings for Aura Biosciences, projecting a significant upside. Mizuho Securities and RBC Capital also reiterated Buy ratings for …

Assembly Biosciences earnings beat by $0.53, revenue topped estimates

Form 8K Ensysce Biosciences Inc For: 13 August By Investing.com

This article reports that Ensysce Biosciences Inc. filed a Form 8K on August 13. The company's stock symbol is ENSC, which saw a 14.75% increase. The article provides only this financial filing information without further details on the content of the Form 8K.

Dare Bioscience Reports Q2 2026 Results: Full Earnings Call Transcript

Satellos Bioscience: Q2 Earnings Snapshot

Assembly Biosciences (ASMB) Reports Q2 Loss, Beats Revenue Estimates

Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Beats Revenue Estimates

NovaBridge webcast to cover oncology and ophthalmology programs

NovaBridge Biosciences (Nasdaq: NBP) announced it will host a webcast on Thursday, August 20, 2026, at 9:00 AM ET / 9:00 PM China Standard Time to discuss recent corporate progress and financial results for the first half ended June 30, 2026. The company is …

NovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026

NovaBridge Biosciences announced it will hold a webcast on Thursday, August 20, 2026, to discuss its first half 2026 financial results and corporate progress. The company, a global biotechnology firm focused on oncology and ophthalmology, will host the webcast at 9:00 AM ET/9:00 PM …

Satellos Q2 loss widens to $11.7M, EPS misses estimates

Satellos Bioscience reported a Q2 2026 net loss of $11.7 million, or $0.56 per share, missing analyst estimates due to significantly increased R&D spending on its Phase 2 DMD clinical trials. Despite the widening loss, the company's cash reserves rose to $61.8 million, providing …

Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress

Satellos Bioscience Inc. announced its Q2 2026 financial results, reporting a strong cash position of $61.8 million and progress in its clinical trials for SAT-3247, a drug candidate for Duchenne muscular dystrophy (DMD). The company highlighted favorable safety data from the TRAILHEAD adult DMD …

Satellos reports stable strength in four-adult Duchenne study

Satellos reported its second quarter 2026 financial results, including a net loss of $11.7 million, and provided updates on its clinical progress for SAT-3247 in Duchenne muscular dystrophy (DMD). The company highlighted stable strength and reduced muscle fat in a Phase 2 adult DMD …

Satellos Bioscience (NASDAQ: MSLE) ramps Duchenne R&D and strengthens cash

Satellos Bioscience reported increased net losses in the first half of 2026 due to higher R&D and G&A expenses, driven by advancing its Duchenne muscular dystrophy (DMD) clinical programs, SAT-3247. Despite widening losses, the company significantly strengthened its cash position to $61.8 million through …

Form 8K Arcadia Biosciences Inc For: 13 August By Investing.com

This article reports on the filing of a Form 8K by Arcadia Biosciences Inc. on August 13. The company's stock symbol is RKDA, and its shares experienced a 9.60% increase. The brief announcement provides no further details about the content of the 8K filing.

Assembly Biosciences (NASDAQ:ASMB) Issues Quarterly Earnings Results, Beats Expectations By $0.52 EPS

Assembly Biosciences (NASDAQ:ASMB) reported quarterly earnings, beating analyst expectations with an adjusted loss of $0.20 per share, $0.52 better than forecast, and revenue of $13.37 million, exceeding estimates of $8.60 million. Following the news, shares rose significantly by $2.89 to $29.95 on high trading …

Alamar Biosciences (ALMR): Yuling Luo discloses 6.4% beneficial ownership stake

Yuling Luo has disclosed a 6.4% beneficial ownership stake in Alamar Biosciences (ALMR) through a Schedule 13G filing. This amounts to 4,528,718 shares, including those with sole and shared voting/dispositive power, and shares exercisable via stock options within 60 days. The ownership percentage is …

Transcript : Microbix Biosystems Inc., Q3 2026 Earnings Call, Aug 13, 2026

Ensysce Q2 Results: EPS beats estimate, sales up 16% vs view

Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Lags Revenue Estimates

Caribou Biosciences, Inc. (CRBU) reported a Q2 loss of $0.24 per share, outperforming the Zacks Consensus Estimate of a $0.33 loss. However, the company missed revenue estimates, posting $1.5 million against an expected $2.5 million. The stock currently holds a Zacks Rank #3 (Hold), …

Satellos Bioscience Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Arcadia Biosciences: Q2 Earnings Snapshot

Form 8K Inhibrx Biosciences Inc For: 13 August By Investing.com

This article reports on the filing of a Form 8K by Inhibrx Biosciences Inc. for August 13. The brief notice highlights the company's regulatory submission without providing further details on its content. It includes the stock symbol INBX, which saw a slight decrease.

Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Ensysce Biosciences announced its Q2 2026 financial results, highlighted by the acquisition of Cy Biopharma, Inc., which adds CY200 for Complex Regional Pain Syndrome (CRPS) to its pipeline. This acquisition, coupled with private placement financings, provides up to $77 million in new funding, extending …

Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Caribou Biosciences has released its financial results for the second quarter of 2026, alongside a business update. The report details the company's financial performance and highlights recent developments in its operations and strategic initiatives.

Caribou Biosciences reports Q2 2026 results: $1.5M licensing revenue, $24.3M GAAP net loss

Caribou Biosciences reported its Q2 2026 financial results, showing $1.5 million in licensing revenue and a GAAP net loss of $24.3 million. The company holds $113.8 million in cash and expects these funds to support operations through the end of 2027. Business highlights include …